Meropenem Generis Phar (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, causing cell‑wall weakening, osmotic lysis, and bacterial death. Its high affinity for a wide range of PBPs gives it activity against many Gram‑negative, Gram‑positive, and anaerobic organisms.

The dosage of Meropenem Generis Phar is determined by the prescribing clinician based on infection severity, site, and patient factors such as renal function. Dosing regimens are individualized and may range from 500 mg to 2 g administered intravenously every 8 hours, but the exact schedule must be set by a qualified healthcare professional.

Safety data for Meropenem in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Meropenem belongs to the carbapenem class, offering broader Gram‑negative and anaerobic coverage than most cephalosporins and penicillins. Compared with other carbapenems such as imipenem‑cilastatin, Meropenem has a lower risk of nephrotoxicity and does not require co‑administration of a renal protectant. It is often chosen for multidrug‑resistant infections where other agents fail.

Meropenem Generis Phar should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under aseptic conditions to maintain sterility.

Meropenem is supplied as a sterile powder for intravenous infusion. It must be reconstituted with the appropriate diluent, then further diluted in compatible IV fluids. Administration is typically via a controlled infusion over 15‑30 minutes, although extended infusions may be used in specific clinical scenarios as directed by the prescriber.

Serious adverse events include seizures (especially in patients with renal impairment or CNS disease), severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, acute renal failure, and hematologic abnormalities like neutropenia. Prompt recognition and medical intervention are essential if any of these occur.

Meropenem is contraindicated in patients with a known hypersensitivity to carbapenems or other β‑lactam antibiotics. Caution is advised for individuals with severe renal impairment who cannot receive dose adjustments, and for patients with a history of seizures unless benefits outweigh risks. Clinicians should evaluate each case before prescribing.